Inhalation Sciences submits Project Report and Summary Data to the FDA for Final Review
(Stockholm, Sweden, 9 January 2025) Inhalation Sciences Sweden AB (ISAB) is proud to announce the submission of the project report and summary data to the U.S. Food and Drug Administration (FDA) for final review and approval. This marks a key milestone in ISAB’s ongoing FDA BAA (Broad Agency Agreement) Contract 75F40122C00197 for a collaborative research project which evaluates the discriminative dissolution potential of its innovative DissolvIt[®] system for assessing drug formulations designed for inhalation therapy.The DissolvIt[®] system is designed to address a critical need in